1 drug(s) with this reaction
625 total reports
Colorectal Cancer Metastatic has been reported as an adverse reaction across 1 drug(s) manufactured by Amgen Inc in the FDA Adverse Event Reporting System (FAERS) database. A combined total of 625 adverse event reports mention colorectal cancer metastatic in connection with Amgen Inc products.
This page provides a breakdown of which Amgen Inc drugs are most commonly associated with colorectal cancer metastatic, along with report counts and links to detailed safety analyses for each medication. Understanding which drugs from a single manufacturer share a common adverse reaction can help patients and healthcare providers identify potential class-wide safety patterns.
The following Amgen Inc drugs have colorectal cancer metastatic listed in their FDA adverse event reports, sorted by report count:
In addition to colorectal cancer metastatic, the following adverse reactions have been reported across Amgen Inc's drug portfolio:
1 drug(s) manufactured by Amgen Inc have colorectal cancer metastatic listed in their FDA adverse event reports: PANITUMUMAB.
There are a combined 625 reports of colorectal cancer metastatic across 1 Amgen Inc drug(s) in the FDA adverse event database.